Why Sotera Health Company’s (SHC) Stock Is Up 5.56%
As of Thursday, August 06, Sotera Health Company’s SHC share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Sotera Health Company (SHC)
Sotera Health Company SHC
$19.57
0.35
1.82%
August 21, 2026 4:00:00 PM
EST
Volume: 2,350,204
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Commentary & Analysis
What You Need to Know About Sotera Health Company's Q3 Earnings
Sotera Health Company's fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (SHC) missed or beat analyst's expectations.Michael Rose
Is Sotera Health Company (SHC) Overvalued?
We dive into why Sotera Health Company (SHC) could be considered overvalued on 2026-07-29, based on AAII’s Value Score and Grade.Tudor Pop
Which Is a Better Investment, AbCellera Biologics Inc. or Sotera Health Company Stock?
Learn more about whether AbCellera Biologics Inc. or Sotera Health Company is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Sotera Health Company’s (SHC) Stock Is Down 6.21%
As of Tuesday, May 05, Sotera Health Company’s SHC share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | SHC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,584.8 | $3,022.1 | 69% |
|
| Shares Out (Mil) | 288.1 | 96.5 | 82% |
|
| Institutional Ownership | 96.7% | 89.6% | 71% |
|
| Float (Mil) | 184.8 | 71.5 | 72% |
|
| Beta | 1.78 | 1.22 | 89% |
|
| Avg Daily Volume (000s) | 3,165 | 702 | 88% |
|
| Price Change (52-week) |
20.1% | 90.5% | 61% |
|
| Growth | SHC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.3% | 7.8% | 47% |
|
| Net Income (5yr) | 32.1% | (13.7%) | 86% |
|
| EPS (5yr) | 29.7% | 0.7% | 81 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 7.1% | (15.0%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | $0.269 | $0.985 | $1.075 | |
| Month Ago EPS | $0.271 | $0.966 | $1.060 | |
| # Rev Up | 2 | 1 | 4 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.272 | $0.971 | $1.061 | |
| Year/Year Chg | 43.1% | 264.8% | 339.6% | |
| Financials | SHC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,216 | $800 | 53% |
|
| Net Income (TTM) (Mil) | $164 | ($31) | 66% |
|
| EPS (TTM) | $0.574 | ($0.300) | 55% |
|
| Operating Cash Flow (TTM) (Mil) | $292 | $47 | 64% |
|
| Net Cash Flow (TTM) (Mil) | $23 | $5 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $2,245 | $270 | 76% |
|
| Enterprise Value (Q1) (Mil) | $7,325 | $3,617 | 69% |
|
| Valuation | SHC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.40 | 3.75 | 87% |
|
| P/E | 34.5 | 40.6 | 74% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.2 | 5.5 | 50% |
|
| Ratios | SHC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 55.0% | 47.7% | 67% |
|
| Net Margin | 13.4% | (3.2%) | 70% |
|
| ROA | 5.0% | (4.3%) | 72% |
|
| ROE | 27.8% | (7.9%) | 86% |
|
| Liabilities to Assets | 79.9% | 42.0% | 74% |
|
| F-Score | 7 | 5 | 82% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.7 |
